Health News
| 2011-04-22: |
| Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA( R ) ( Edoxaban ), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism After Major Orthopedic Surgery Tokyo ( PRN/ots ) - Daiichi Sankyo Company, Limited ( hereafter, Daiichi Sankyo ), announced today that the company has received its first marketing approval for LIXIANA( R ) ( JAN: Edoxaban Tosilate Hydrate, INN:edoxaban ) 15 mg and 30 mg tablets, by the Ministry of Health, Labor and Welfare in (...) |
| 2011-04-21: |
| Pevion's shareholders elect Jean - Paul Prieels, former Head Research GSK Vaccines, to its Board Ittigen / Bern, Switzerland ( na Originaltextservice ) - Pevion Biotech AG today announced that Jean - Paul Prieels has joined its Board of Directors. Until January 2011, Dr. Prieels was Senior Vice President Research and Development at GlaxoSmithKline Biologicals. Jean - Paul Prieels joined GlaxoSmithKline (...) |
| 2011-04-19: |
| Investors Flock to German Medical Biotech Industry / BayBio Annual Conference Berlin / Burlingame ( California ) ( na Originaltextservice ) - Germany is setting the bar in biotechnology and investors from all over the world are taking notice. Venture capital investments doubled from 2009 to 2010 to over $420 million. Industry revenues continue to grow, according to (...) |
| 2011-04-19: |
| World Malaria Day: when a simple initiative conveys great results Limburgerhof, Germany ( na Originaltextservice ) - - Interceptor® bed nets key factor for decrease in malaria infection in Jabote community ( Brazil ) - Positive spiral effect: less malaria, more kids in school - Cross reference: Pictures are available via epa european pressphoto agency and (...) |
| 2011-04-19: |
| Zebinix( R ) Now Available in Greece Hatfield, England ( PRN/ots ) - Zebinix( R ) ( eslicarbazepine acetate ), an add - on ( adjunctive ) therapy for adults with partial - onset seizures, with or without secondary generalisation ( where the seizure extensively affects consciousness of the patients by propagation to both sides of the brain ), has recently been launched in (...) |
| 2011-04-18: |
| Global Phase III Trial With Selective c - MET Inhibitor Tivantinib ( ARQ 197 ) Starts Enrolling Patients in Europe Munich ( PRN/ots ) - Daiichi Sankyo announced today that it has begun enrolling patients in Europe into a large, multinational phase III trial of tivantinib ( ARQ 197 ). Tivantinib is an investigational small molecule inhibitor of the c - MET receptor tyrosine kinase in final phase of (...) |
| 2011-04-15: |
| Study Suggests up to 135,000 Lives Could be Saved in Europe Each Year Through Better Control of Cardiovascular Risk Factors Geneva ( PRN/ots ) - Results from a large pan - European study suggest that up to 135,000 deaths from cardiovascular disease ( CVD ), such as heart attacks and strokes, could be prevented in Europe each year though better control of risk factors including high blood pressure, high (...) |
| 2011-04-13: |
| Helsinn and Taiho Pharmaceutical Co., Ltd. to Extend Relationship / License Agreement for Japan on Potential New Therapy in the Prevention of Chemotherapy - induced Nausea and Vomiting ( CINV ) Lugano, Switzerland and Tokyo, Japan ( na Originaltextservice ) - Helsinn Group of Switzerland and Taiho Pharmaceutical Co., Ltd., Japanese licensee of Helsinn's second generation 5 - HT3 receptor antagonist palonosetron, announce today the signing on April 12, of a licensing agreement granting Taiho the (...) |
| 2011-04-12: |
| Press Release OctreoPharm Sciences GmbH Closes Financing Round for Cancer Diagnostic Berlin ( na Originaltextservice ) - OctreoPharm Sciences GmbH, a specialist for contrast media in Nuclear Medicine, was able to successfully close a financing round for the clinical development of its cancer diagnostic SOMscan®. With the nearly EUR 5 million which were brought up by (...) |
| 2011-04-12: |
| Pieris and Daiichi Sankyo Sign Therapeutic Collaboration to Develop Anticalin( R ) Therapeutics Freising, Germany ( na Originaltextservice ) - Pieris AG announced today the signature of a collaboration and license agreement with Daiichi Sankyo Company Limited ( hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568 ), under which Pieris will apply its proprietary Anticalin scaffold technology (...) |
| 2011-04-11: |
| Veterinarians and Pet Owners Urged to act Upon Evolving Dangers Posed by CVBDs Monheim, Germany ( PRN/ots ) - Leading experts from around the world came together today to share their latest research findings at the 6th Canine Vector Borne Disease ( CVBD ) forum in Nice, France and call for greater awareness of the dangers posed to animals and humans (...) |
| 2011-04-11: |
| Pieris to Present at BioCentury Future Leaders in the Biotech Industry Conference Freising ( na Originaltextservice ) - Pieris AG announced today that Stephen Yoder, Chief Executive Officer, is scheduled to present at the 18th Annual BioCentury Future Leaders in the Biotech Industry Conference 2011, to be held Friday, April 15, 2011 at the Millennium Broadway Hotel (...) |
| 2011-04-11: |
| European Survey Reveals Wide - Reaching Impact of eczema on Quality of Life and Emotional Wellbeing of Children and Their Families London ( PRN/ots ) - New survey data released today demonstrate that childhood eczema can have a detrimental effect on quality of life not only for the children who live with the disease, but also for their families.[1a] The survey, which was carried out (...) |
| 2011-04-08: |
| Amgen Establishes Commercial Operations in Brazil Thousand Oaks, California ( PRN/ots ) - Amgen , the world's largest biotechnology company, announced today the expansion of its operations in Brazil, including the acquisition of Bergamo, a privately - held Brazilian pharmaceutical company. Amgen has also agreed to reacquire rights in Brazil to its products (...) |
| 2011-04-06: |
| joimax® - the 1st US TESSYS® User Meeting in Denver, Colorado, USA heralds 10 - year anniversary celebrations Karlsruhe ( na Originaltextservice ) - At the same time joimax® Inc., the US subsidiary celebrates its fifth anniversary, exhibits at the AANS and for the first time awards the Parviz Kambin prize in the frame of the second international TESSYS® - User Meeting (...) |
| 2011-04-04: |
| Eppendorf licenses technology for thermal cyclers to Labnet International Hamburg ( na Originaltextservice ) - Eppendorf AG has licensed patents covering gradient technology for thermal cyclers to Labnet International for their Labnet® Multigene gradient Thermal Cyclers, including US patent Nos. 6,767,512 and 7,074,367. Eppendorf utilizes the technology in its Eppendorf Mastercycler® pro gradient, Mastercycler (...) |
| 2011-04-04: |
| Miltenyi Biotec is picking up good VYBrations / New flow cytometer MACSQuant® VYB opens up novel avenues in cell analysis Orlando, Florida ( na Originaltextservice ) - Miltenyi Biotec today announces the worldwide release and availability of the MACSQuant® VYB, a compact, benchtop flow cytometer featuring violet, yellow, and blue lasers, and detection of 10 optical parameters. The MACSQuant VYB enables easy but sophisticated (...) |
| 2011-03-30: |
| Amgen to Appeal CHMP Opinion on Vectibix( R ) ( Panitumumab ) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe Thousand Oaks, California ( PRN/ots ) - Amgen announced today that it has submitted a request to the European Medicines Agency ( EMA ) for a re - examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use ( CHMP ) for the use (...) |
| 2011-03-30: |
| Astellas and Medivation Announce Initiation of Phase 2 Clinical Trial Comparing MDV3100 With Bicalutamide in Advanced Prostate Cancer LONDON, STAINES, England and SAN FRANCISCO, March 30, 2011 ( PRN/ots ) - - Astellas Pharma Europe Ltd. and Medivation, Inc. today announced treatment of the first patient in the TERRAIN trial, a Phase 2 comparison of the investigational drug MDV3100, a triple - acting, oral androgen receptor (...) |
| 2011-03-29: |
| Institut Pasteur Shanghai Announces the Creation of its Global Biotech Accelerator Advance BioChina Biovision, Lyon, France ( PRN/ots ) - Institut Pasteur of Shanghai announces today the creation of its global biotech accelerator company Advance BioChina. Advance BioChina is an R&D - focused for - profit organization that positions itself as the gateway to China for global biotech companies. Advance BioChina (...) |
| 2011-03-28: |
| Ocean Nutrition Canada Honours Wilmar International Limited for 2010 Most Significant Contribution to Human Health Award in the Omega - 3 Sector Dartmouth, Nova Scotia ( PRN/ots ) - Ocean Nutrition Canada Limited ( ONC ), the world's largest Omega - 3 EPA/DHA solutions provider, and supplier of MEG - 3( R ) brand Omega - 3 EPA/DHA ( eicosapentaenoic acid/docosahexaenoic acid ) ingredients, is pleased to announce that it recently presented Wilmar International (...) |
| 2011-03-23: |
| Treatment With Prolia( R ) ( denosumab ) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate Thousand Oaks, California ( PRN/ots ) - Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia( R ) ( denosumab ) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis. Adherence to treatment, which includes both (...) |
| 2011-03-23: |
| Prolia( R ) ( denosumab ) Open - Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial Thousand Oaks, California ( PRN/ots ) - Amgen today announced new long - term data showing that during the fourth and fifth years of Prolia( R ) ( denosumab ) treatment, postmenopausal women with osteoporosis receiving Prolia continued with further, statistically significant, year - over - year increases in lumbar spine and total hip (...) |
| 2011-03-21: |
| Phase III Results Show Mirabegron Improves Key OAB Symptoms Tokyo ( PRN/ots ) - Astellas Pharma Inc. ( http://www.astellas.com/en/corporate/ ) today announced the results of two pivotal phase III clinical trials for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder ( OAB ), show mirabegron significantly (...) |
| 2011-03-21: |
| First Social Network for Osteoporosis Launches at Global Patient Conference Valencia, Spain ( PRN/ots ) - On Friday 18 March the International Osteoporosis Foundation ( IOF ) announced the launch of OsteoLink, a new social network for people affected by osteoporosis. Through OsteoLink, the IOF will create the first global online and in - person network dedicated to improving (...) |
| 2011-03-18: |
| Amgen Statement on CHMP Opinion on Vectibix( R ) ( Panitumumab ) Use With Chemotherapy in Metastatic Colorectal Cancer Thousand Oaks, California ( PRN/ots ) - Amgen today issued the following statement: Amgen has received notice that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a negative opinion for Amgen's application to extend the marketing (...) |
| 2011-03-19: |
| The Future of Urology in Question: New Survey Reveals the Top Concerns Facing Specialists Today London and Staines, England ( PRN/ots ) - New research by Astellas Pharma Europe Ltd. today reveals the top three challenges facing urologists across Europe are a lack of funding for research and development; a lack of understanding amongst referrers; and a lack of new treatments (...) |
| 2011-03-18: |
| Philips and World Association of Sleep Medicine Join Efforts to Expand People's Awareness of the Impact of Sleep on Health and Well - Being Amsterdam, The Netherlands ( PRN/ots ) - Royal Philips Electronics announced today a global partnership with the World Association of Sleep Medicine ( WASM ), as official sponsor of World Sleep Day 2011, being held across the globe on Friday, March 18. This partnership illustrates Philips' expanding efforts (...) |
| 2011-03-14: |
| R&D Productivity Measures Consistently Under - Scored and Under - Valued, EvaluatePharma Data Reveals London ( PRN/ots ) - Pharmaceutical R&D productivity is consistently undercounted. Most reports fail to fully count the number of new drugs that reach the market, missing out on billions of dollars of sales generated by R&D investment, an analysis of EvaluatePharma data shows. Most counts (...) |
| 2011-03-10: |
| Agendia Hires David Macdonald as Chief Operating Officer, Mark Willig as Executive VP of North American Sales, and Doug Bradley as Vice President of Global Marketing Irvine, California and Amsterdam ( PRN/ots ) - Agendia, a world leader in molecular cancer diagnostics, today announced the hiring of David Macdonald as the company's Chief Operating Officer, Mark Willig as Executive Vice President of North American Sales, and Doug Bradley as Vice President (...) |
| 2011-03-10: |
| Nordion Reports First Quarter 2011 Financial Results Ottawa ( PRN/ots ) - Highlights: - Extended sales contract with major customer Lantheus Medical Imaging until 2013 - Announced return of cash to shareholders through dividend and Normal Course Issuer Bid ( NCIB ) - Achieved cost savings following completion of strategic repositioning Nordion (...) |
| 2011-03-08: |
| ProFibrix Initiates Phase II With Lead Hemostasis Product Fibrocaps( TM ) in US and Europe Leiden, The Netherlands and Seattle ( PRN/ots ) - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has initiated a prospective, multi - center Phase II study with its lead product Fibrocaps at up to 20 sites, including (...) |
| 2011-03-08: |
| Chronic Kidney Disease and Cardiovascular Risk Strasbourg, France ( PRN/ots ) - The European Kidney Health Alliance ( EKHA ) and World Kidney Day ( WKD ) organisations today call for urgent European Union ( EU ) action to curb the increasing burden of chronic kidney disease ( CKD ) and associated diseases. The Members of European Parliament ( MEP ) (...) |
| 2011-03-07: |
| The Disease Modifying Effect of Chondroitin Sulphate in Patients With Knee Osteoarthritis has Been Confirmed by MRI Barcelona ( PRN/ots ) - A group of Canadian researchers led by Prof. Jean - Pierre Pelletier, Head of the Osteoarthritis Research Unit, at the University of Montreal Hospital Research Centre, published a clinical trial, in which they confirm, for the first time using quantitative Magnetic Resonance (...) |
| 2011-03-04: |
| Burcon Enters License Agreement With ADM for CLARISOY( R ) Protein Technology Vancouver, British Columbia ( PRN/ots ) - Burcon NutraScience Corporation announced today that the company has entered into a license agreement with Archer Daniels Midland Company ( "ADM" ) for the worldwide production, distribution and sale of Burcon's CLARISOY( R ) soy protein. CLARISOY is a unique soy protein product that (...) |
| 2011-03-04: |
| Philips Shows New Approach and Advances in Clinical Collaboration at European Congress of Radiology 2011, to Drive Innovation and Efficiency Vienna ( PRN/ots ) - At the European Congress of Radiology ( ECR ) 2011, Royal Philips Electronics is ushering in a new era in radiology science with Imaging 2.0, a concept fueled by integration of technology, clinician and patient. Showcasing its commitment to pioneering innovative, cost - effective (...) |
| 2011-03-04: |
| /C O R R E C T I O N - - Bristol - Myers Squibb and AstraZeneca/ Paris and London ( PRN/ots ) - In the news release, "ONGLYZA( R ) Becomes the First DPP - 4 Inhibitor Available for Use in Europe" issued on 4 Mar 2011 08:00 GMT, by Bristol - Myers Squibb and AstraZeneca NYSE:AZN over PR Newswire, we would like (...) |
| 2011-03-04: |
| ONGLYZA( R ) Becomes the First DPP - 4 Inhibitor Available for Use in Europe Paris and London ( PRN/ots ) - Bristol - Myers Squibb Company ( http://www.bms.com ) and AstraZeneca ( http://www.astrazeneca.com ) today announced that the European Commission has approved a label update for ONGLYZA( R ) ( saxagliptin ) in the treatment of adults with type 2 diabetes who have moderate or severe renal impairment. (...) |
| 2011-03-01: |
| BARACLUDE( R ) ( entecavir ) Approved by the European Commission for the Treatment of Chronic Hepatitis B in Adult Patients With Evidence of Decompensated Liver Disease Paris ( PRN/ots ) - Bristol - Myers Squibb announced today that BARACLUDE( R ) ( entecavir ) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B ( CHB ) in adult patients with evidence of decompensated liver disease. BARACLUDE( r ) was already approved in Europe (...) |
| 2011-02-23: |
| Agendia Receives Fifth FDA Clearance for Industry Leading MammaPrint( R ) Assay Irvine, California and Amsterdam ( PRN/ots ) - Agendia, a world leader in molecular cancer diagnostics, today announced that the company has received its fifth U.S. Food and Drug Administration ( FDA ) clearance for MammaPrint( R ), its widely used breast cancer recurrence assay. The new clearance is (...) |
| 2011-02-23: |
| Sanofi Pasteur Supports Polio Eradication at First International Stock Exchange Event LYON, France and SWIFTWATER, Pennsylvania, February 23, 2011 ( PRN/ots ) - - Sanofi Pasteur, the vaccines division of sanofi - aventis Group , today will participate in the first international bell - ringing event by a company listed on NYSE Euronext. The events will acknowledge past successes and (...) |
| 2011-02-22: |
| Pieris to Present Interim Data from the Phase I Clinical Trial of PRS - 050 at Molecular Medicine Tri - Conference Freising, Germany ( na Originaltextservice ) - Pieris AG announced today the upcoming presentation of new preclinical and interim Phase I clinical trial data for its PRS - 050 Anticalin( program, currently under evaluation for the treatment of cancer. Dr. Laurent Audoly, Chief Scientific Officer (...) |
| 2011-02-21: |
| Nordion Signs Share Purchase Agreement to Divest MDS Nordion S.A. Ottawa, Canada ( PRN/ots ) - Nordion Inc. , a leading provider of products and services to the global health science market, today announced it has signed a share purchase agreement ( SPA ) with Best Medical Belgium ( Best Medical ) for the divestiture of the Company's Belgian operations, (...) |
| 2011-02-21: |
| Sanofi Pasteur and International Vaccine Institute Partner Against Dengue Lyon, France ( PRN/ots ) - Sanofi Pasteur, the vaccines division of sanofi - aventis Group , announced today that it is partnering with the International Vaccine Institute ( IVI ) to support the recently launched Dengue Vaccine Initiative ( DVI ). Sanofi Pasteur and the IVI will aim to raise (...) |
| 2011-02-15: |
| The World Heart Federation, sanofi - aventis and Boehringer Ingelheim Announce Collaboration on Worldwide AF Awareness Campaign Geneva ( PRN/ots ) - The World Heart Federation, sanofi - aventis and Boehringer Ingelheim have announced their collaboration on the AF AWARE ( Atrial Fibrillation AWareness And Risk Education ) campaign today, to raise awareness of atrial fibrillation ( AF ) and its links to severe consequences including cardiovascular ( CV ) mortality, (...) |
| 2011-02-10: |
| Zebinix, Novel Once - Daily Anti - Epileptic Treatment, Launches in Spain Hatfield, England ( PRN/ots ) - Zebinix( R ) ( eslicarbazepine acetate ), an add - on ( adjunctive ) therapy for adults with partial - onset seizures, with or without secondary generalisation ( where the seizure spreads to both sides of the brain ), has been launched today in Spain by Eisai and BIAL in (...) |
| 2011-02-07: |
| Astellas Enters into Partnership With Optimer on Life - Saving Antibiotic Fidaxomicin Staines, England ( PRN/ots ) - Astellas Pharma Europe Ltd. announced today that it has entered into an exclusive collaboration and license agreement with Optimer Pharmaceuticals Inc., San Diego for the development and commercialisation of fidaxomicin, an investigational antibiotic for Clostridium difficile infection ( CDI ) in Europe and (...) |
| 2011-02-04: |
| First Study Estimates Economic Impact of Dengue Illness in Americas at $2.1 Billion Per Year Deerfield, Illinios ( PRN/ots ) - The first assessment of the total cost of dengue illness in the Americas reveals the economic burden to be approximately $2.1 billion per year, exceeding that from other viral illnesses including human papillomavirus ( HPV ) and rotavirus. Results of the study (...) |
| 2011-02-01: |
| Aircraft Medical Wins Long - running Video Laryngoscope Patent Litigation Against Verathon Edinburgh, Scotland ( PRN/ots ) - Aircraft Medical Ltd ( "Aircraft" ) is pleased to announce that judgment has been passed in its favour in the long running patent infringement litigation between it and US rival Verathon Medical Inc. ( "Verathon" ), a subsidiary of Roper Industries Inc. Heard in (...) |
| 2011-02-01: |
| Premiere: World's Most Sustainable Washroom Swalmen, The Netherlands ( PRN/ots ) - The world's most sustainable washroom was on show at the Facilities Exhibition in the Brabant Halls in Den Bosch, the Netherlands. Van Houtum, based in Swalmen, the Netherlands, used the event to present a completely equipped washroom, supplied with (...) |
| 1 2 3 4 5 6 7 8 9 10 11 more... |
